Given the potential clinical utility of BDX008 for optimization of advanced melanoma treatment, we sought to further validate the test in an independent cohort of patients with known BRAF mutation status treated with anti-PD-1 therapy in an unselected population previously treated with ipilimumab. Here, BRAF is linked to melanoma.